Brain imaging for inflammation in Alzheimer's disease
Part of Brain & nervous system clinical trials.
This trial tests a new radioactive imaging agent that targets a protein (TSPO) in the brain, which is linked to inflammation. The goal is to see if it can help visualize brain inflammation in people with Alzheimer's disease, potentially aiding in diagnosis and monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a formal diagnosis of Alzheimer's disease, confirmed by a positive amyloid PET scan (a brain scan that shows amyloid plaques).
- You have already had a tau PET scan (another brain scan for a protein linked to Alzheimer's).
- You have not taken anti-inflammatory drugs (like steroids or immunosuppressants) in the last 14 days.
- You do not have other brain diseases (like stroke, Parkinson's, brain tumors, or psychiatric conditions) or serious heart, lung, liver, or kidney problems.
- You must not have metal implants (like pacemakers or stents) that would prevent an MRI, and you must be able to tolerate lying still in an MRI scanner (no severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.
This study uses a special PET scan to look for inflammation in the brains of people with Alzheimer's or related dementias. It may help researchers understand how inflammation affects memory and thinking problems.
This study uses a special PET scan to take pictures of abnormal tau protein in the brain. It aims to see if the scan results match what is found in brain tissue after death, which could help improve diagnosis of Alzheimer's and related conditions.
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
This study tests a PET scan “tracer” medicine called [18F]MK-6240 to see how tau protein changes show up in the brain. It may help researchers measure disease-related brain changes in people with normal thinking or mild dementia.
This Phase 1 study tests a PET scan to measure inflammation-related changes in the brain using a medication called ketoprofen. It may help researchers understand which people with certain brain diseases could benefit from treatments aimed at inflammation.
Hear when a new Alzheimer's Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.